Novanﾒs NITRICILﾙ technology showed In vitro antiviral effect against SARS-CoV-2 in human airway infection model
On Oct. 14, 2020, Novan announced positive in vitro results showing the potential efficacy of its NITRICILﾙ platform…
Tevogen Bio submitted IND for T cell treatment in COVID-19
On Oct. 14, 2020, Tevogen Bio announced that its Investigational New Drug (IND) application to develop a COVID-19…
DOD awarded $481 million to Cue Health to increase domestic production capacity of point-of-care testing
On Oct. 13, 2020, the Department of Defense (DOD), on behalf of the U.S. Department of Health and…
COVID-19 vaccine with Dynavaxﾒs CpG 1018 adjuvant received Taiwan government subsidy with first dosage
On Oct. 13, 2020, Medigen Vaccine Biologics (MVC) and Dynavax Technologies announced that MVC had obtained a Taiwan…
NIH-funded study linked adolescent brain differences to increased waist circumference
On Oct. 13, 2020, the National Institute on Drug Abuse (NIDA) and nine other institutes, all part of…
Roche launched laboratory SARS-CoV-2 antigen test to support high-volume testing of suspected COVID-19 patients
On Oct. 13, 2020, Roche announced that it intended to launch a high-volume SARS-CoV-2 Antigen test as an…
NIH study to identify promising COVID-19 treatments for larger clinical trials
On Oct. 13, 2020, the National Institute of Allergy and Infectious Diseases (NIAID), launched a study designed to…
NeoGenomics expanded global footprint in pharma services with new clinical research laboratory in Suzhou, China
On Oct. 13, 2020, NeoGenomics announced plans to open a state-of-the-art research laboratory in China in association with…
Apogenix advanced clinical development of CD95L inhibitor asunercept in European COVID-19 phase II trial
On Oct. 13, 2020, Apogenix announced that the first patient has been enrolled in the ASUNCTIS trial. The…
Cue received $481 million award to expand domestic production capacity of molecular, point-of-care COVID-19 tests
On Oct. 13, 2020, Cue Health announced a $481 Million award from the Department of Defense (DOD), on…
Eli Lilly paused trial of antibody drug Trump touted as COVID-19 ‘cure’ over safety concern
On Oct. 13, 2020, Eli Lilly announced that the government-sponsored clinical trial of its COVID-19 antibody treatment similar…
New CAR T-Cell therapy approved and available at Roswell Park for lymphoma patients
On Oct. 13, 2020, Roswell Park Comprehensive Cancer Center announced that it had been approved to administer the…
Thermo Fisher Scientific expanded COVID-19 test portfolio with two new antibody tests
On Oct. 12, 2020, Thermo Fisher Scientific introduced two new SARS-CoV-2 antibody tests: the Thermo Scientific OmniPATH COVID-19…
Johnson & Johnson temporarily paused all dosing in Janssen COVID-19 vaccine candidate clinical trials
On Oct. 12, 2020, Johnson & Johnson announced temporarily paused further dosing in all our COVID-19 vaccine candidate…
The CDC released a new national antibiotic resistance plan
On Oct. 9, 2020, the CDC released a new National Action Plan that directed federal agencies to accelerate…
Rigel announced first patients enrolled in trial of fostamatinib in hospitalized COVID-19 patients in collaboration with Inova
On Oct. 9, 2020, Rigel Pharma announced enrollment of the first patients in a multicenter, Phase 2 trial…
OPKO Health’s BioReference Laboratories launched COVID-19 testing program for New York City schools
On Oct. 9, 2020, OPKO Health subsidiary BioReference Labs, New York City, the Department of Health, New York…
Pfizer Canada and BioNTech initiated rolling submission to Health Canada for SARS-CoV-2 vaccine candidate
On Oct. 9, 2020, Pfizer and BioNTech announced the initiation of a rolling submission to Health Canada for…
NIAID clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
NIH launched the Serological Sciences Network for COVID-19, announced grant and contract awardees
On Oct. 8, 2020, the National Cancer Institute (NCI) launched the Serological Sciences Network for COVID-19 (SeroNet), an…
NIH clinical trial testing hyperimmune intravenous immunoglobulin plus remdesivir to treat COVID-19 began
On Oct. 8, 2020, a clinical trial to test the safety, tolerability and efficacy of a combination treatment…
One stillbirth occurs every 16 seconds, according to first ever joint UN estimates
On Oct. 8, 2020, UNICEF, WHO, the World Bank Group and the Population Division of the United Nations…
FDA awarded grants to fund clinical trials to advance development of products for treatment of rare diseases
On Oct. 8, 2020, the FDA announced that it had awarded six new clinical trial research grants to…
Gilead Sciences signed joint procurement agreement with European Commission for Vekluryﾮ (remdesivir)
On Oct. 8, 2020, Gilead Sciences and the European Commission signed a joint procurement agreement (JPA) that enabled…
Gilead Sciences updated supply and distribution of Vekluryﾮ (remdesivir) in the US
On Oct. 8, 2020, The New England Journal of Medicine (NEJM) published the final results from the National…
Emergent BioSolutionsﾒ COVID-19 product candidate included in NIH-sponsored phase 3 clinical trial
On Oct. 8, 2020, Emergent BioSolutions announced the initiation of the Phase 3 clinical trial that will evaluate…
Baricitinib had significant effect on recovery time, most Impactful in COVID-19 patients requiring oxygen
On Oct. 8, 2020, Eli Lilly and Incyte shared additional data showing baricitinib in combination with remdesivir reduced…
Yale Cancer Center received NIH grant to fund COVID-19 research in patients with hematologic cancers
On Oct. 8, 2020, the National Institutes of Health (NIH) awarded a Research Project Cooperative Agreement grant to…
Johnson & Johnson announced EC approval of agreement to supply 200 million doses of COVID-19 vaccine candidate
On Oct. 8, 2020, Johnson & Johnson announced the European Commission, acting on behalf of the European Union…
Caladrius Biosciences opened study of CLBS119 to repair COVID-19-induced lung damage
On Oct. 8, 2020, Caladrius Biosciences announced that it had opened its proof-of-concept study of CLBS119 as a…